Integra Lifesciences Holdings Corp (IART) · Oct 2, 2026 · Earnings

Integra earnings: flooding cuts 2026 guidance as Q3 revenue misses consensus

Guidance cut — FY26 adjusted EPS cut to $2.30–$2.40 from $2.40–$2.50

Integra’s preliminary Q3 earnings show flooding damage extending into 2027, pushing revenue and adjusted EPS guidance lower despite solid cash flow.

Integra is in an operational repair phase: it is trying to restore product availability, relaunch key tissue-reconstruction products, and rebuild commercial execution after earlier manufacturing and supply problems. Its portfolio is weighted toward neurosurgery and regenerative medicine, with management previously highlighting improving supply reliability and the planned SurgiMend relaunch.

The flooding is now a multi-quarter earnings problem, not just a third-quarter interruption. Integra says the Cincinnati disruption reduced third-quarter revenue by about $7 million and expects another $15 million to $20 million hit in the fourth quarter, with full manufacturing recovery only in the second quarter of 2027. 〔0〕

The full-year outlook was cut materially. Revenue guidance fell to $1.634 billion–$1.654 billion from $1.654 billion–$1.695 billion, while adjusted EPS guidance fell to $2.30–$2.40 from $2.40–$2.50. This is the clearest signal in the filing: recovery timing and lost production are worse than the company assumed in July, even though management says the broader business is improving.

MetricPreliminary Q3 2026Prior company outlook / comparisonMarket reference
Revenue$410M–$412M$410M–$425M Q3 outlook~$424.6M consensus
Adjusted EPS$0.55–$0.59$0.53–$0.61 Q3 outlook~$0.57 consensus
FY2026 revenue$1.634B–$1.654B$1.654B–$1.695B prior guidance—
FY2026 adjusted EPS$2.30–$2.40$2.40–$2.50 prior guidance—
Q3 operating cash flowGreater than $85M——
FY2026 operating cash flow$190M–$200M——

Q3 is weaker mainly on revenue, while EPS is roughly in line. The preliminary revenue range is below the published consensus of approximately $424.6 million, while the $0.55–$0.59 adjusted EPS range brackets the roughly $0.57 consensus. The filing therefore reads less like a clean quarterly miss than a negative reset to the recovery path.

Cash generation is the main offset, but it does not undo the operational setback. Integra expects more than $85 million of third-quarter operating cash flow and $190 million–$200 million for the year, supporting its deleveraging and recovery efforts. The company also says it is using inventory and alternate suppliers to limit customer disruption, but the extended Cincinnati ramp means supply constraints remain part of the business story through at least the first half of 2027.

Bottom line: This filing turns a known flooding event into a quantified, multi-quarter drag. The business is still generating cash and making operational progress, but the lower full-year guidance confirms that recovery will take longer and cost more than previously expected.

What to watch next

Q3 results conference call, October 2026

Original filing on SEC EDGAR

More Integra Lifesciences Holdings Corp news

Integra earnings: flooding cuts 2026 guidance as Q3 revenue misses consensus | IART Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.